{"id":452409,"date":"2026-03-17T23:13:21","date_gmt":"2026-03-17T23:13:21","guid":{"rendered":"https:\/\/www.europesays.com\/es\/452409\/"},"modified":"2026-03-17T23:13:21","modified_gmt":"2026-03-17T23:13:21","slug":"la-combinacion-de-pembrolizumab-y-enfortumab-mejora-la-supervivencia-en-cancer-de-vejiga-im-medico","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/es\/452409\/","title":{"rendered":"La combinaci\u00f3n de pembrolizumab y enfortumab mejora la supervivencia en c\u00e1ncer de vejiga – IM M\u00e9dico"},"content":{"rendered":"
    \n
  1. La combinaci\u00f3n de pembrolizumab y enfortumab mejora la supervivencia en c\u00e1ncer de vejiga<\/a>  IM M\u00e9dico<\/li>\n
  2. Buenos datos de ‘Keytruda’ m\u00e1s ‘Padcev’ en c\u00e1ncer de vejiga m\u00fasculo-invasivo elegibles para cisplatino<\/a>  Infosalus<\/li>\n
  3. Enfortumab vedotina y pembrolizumab reducen un 47% el riesgo de recurrencia en c\u00e1ncer de vejiga m\u00fasculo-invasivo<\/a>  iSanidad<\/li>\n
  4. Un tratamiento combinado presenta datos positivos en c\u00e1ncer de vejiga<\/a>  Redacci\u00f3n M\u00e9dica<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"La combinaci\u00f3n de pembrolizumab y enfortumab mejora la supervivencia en c\u00e1ncer de vejiga  IM M\u00e9dico Buenos datos de ‘Keytruda’…\n","protected":false},"author":2,"featured_media":452410,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[11650,1066,55939,9926,9781,94276,94274,25,24,1292,4806,39270,165,55940,4648,31,8719,94275,33841,1817,9928,1086,8013,885,166,23,8768,13151,11820],"class_list":["post-452409","post","type-post","status-publish","format-standard","has-post-thumbnail","category-salud","tag-b","tag-cancer","tag-cisplatino","tag-combinacion","tag-completa","tag-elegibles","tag-enfortumab","tag-es","tag-espana","tag-estudio","tag-eventos","tag-evidencian","tag-health","tag-keynote","tag-libre","tag-mayor","tag-mejora","tag-mibc","tag-msd","tag-pacientes","tag-patologica","tag-pembrolizumab","tag-respuesta","tag-resultados","tag-salud","tag-spain","tag-supervivencia","tag-tasas","tag-vejiga"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@es\/116247055947546508","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/452409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/comments?post=452409"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/452409\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media\/452410"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media?parent=452409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/categories?post=452409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/tags?post=452409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}